Background: ATR-Chk1 signalling network is critical for genomic stability. ATR-Chk1 may
INTRODUCTION
Ataxia telangiectasia mutated and Rad3 related protein (ATR), a serine threonine kinase belonging to the PIKK family (phosphoinositide 3-kinase-like-family of protein kinase), is a key regulator of genomic integrity. ATR is activated by single stranded (ss)-double stranded (ds) DNA junctions generated at stalled replication forks that frequently occur at sites of DNA damage. Activated ATR in turn phosphorylates Chk1 at Ser 345 Our hypothesis is that altered ATR and pChk1 expression may influence breast cancer biology and behaviour, adversely impact clinical outcomes and could be suitable for rational therapeutic targeting in breast cancer. In the current study we have investigated ATR and
Chk1 in large cohorts of primary breast cancers at the protein and mRNA level and have demonstrate for the first time that ATR and pChk1 overexpression is linked to aggressive phenotype and poor outcomes in breast cancer. Pre-clinically, in breast cancer cell lines we
show that phosphorylation and activation of Chk1 at Ser 345 is ATR dependent. ATR gene knockdown or ATR inhibition by small molecule inhibition impairs breast cancer cell growth. We conclude that ATR-pChk1 is a rational target for therapeutic application in breast cancer.
METHODS

Clinical study
Patients: The study was performed in a consecutive series of 1712 patients with primary invasive breast carcinoma who were diagnosed from 1986 to 1999 and entered into the 
Construction of Tissue Microarray (TMA):
TMAs were constructed as previously described (refs) .. Four micron sections of the tissue array block were cut and placed on Superfrost Plus slides for immunohistochemical staining.
Immunohistochemistry (IHC):
The TMAs were immunohistochemically profiled for ATR, phosphorylated Chk1 and other biomarkers included in this study (Supplementary Table S2) as previously described {Sultana, 2013 #4088}. Immunohistochemical staining was performed using the Thermo Scientific Shandon Sequenza chamber system (REF:
72110017), in combination with the Novolink Max Polymer Detection System (RE7280-K:
1250 tests), and the Leica Bond Primary Antibody Diluent (AR9352), each used according to the manufacturer's instructions (Leica Microsystems). The tissue slides were deparaffinised with xylene and then rehydrated through five decreasing concentrations of alcohol (100%, 90%, 70%, 50% and 30%) for two minutes each. Pre-treatment antigen retrieval was performed on the TMA sections using sodium citrate buffer (pH 6.0), heated for 20 minutes at 95 0 C in a microwave (Whirlpool JT359 Jet Chef 1000W). A set of slides were incubated for 18 hours at 4 0 C with the primary mouse monoclonal anti-ATR antibody, clone 1E9
(H00000545-M03, Novus Biologicals, Cambridge, UK), at a dilution of 1:20. A further set of slides were incubated for 60 minutes with the primary rabbit polyclonal anti-phosphorylated Chk1 antibody (Ab58567, Abcam, Cambridge, UK), at a dilution of 1:140.
To validate the use of TMAs for immunophenotyping, full-face sections of 40 cases were stained and protein expression levels of DNA-PKcs antibodies were compared. The concordance between TMAs and full-face sections was excellent (k = 0.8). Positive and negative (by omission of the primary antibody and IgG-matched serum) controls were included in each run.
Evaluation of immunohistochemical staining:
The tumour cores were evaluated by specialist pathologists and oncologists blinded to the clinico-pathological characteristics of patients. Whole field inspection of the core was scored and intensities of nuclear staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. The percentage of each category was estimated (0-100%). H-score (range 0-300) was calculated by multiplying intensity of staining and percentage staining. H-score in a range of 0 -300 was generated. The median H-score of 100 was taken as the cut-off and low ATR or pChk1 expression was classed as H-score of ≤ 100 and >100 was classed as high for ATR or pChk1 expression. Not all cores within the TMA were suitable for IHC analysis as some cores were missing or lacked tumour. Differences between survival rates were tested for significance using the log-rank test.
Multivariate analysis for survival was performed using the Cox hazard model. The proportional hazards assumption was tested using standard log-log plots. Nutrient mixture with 5% horse serum (Gibco, Life Technologies, Paisley, UK), 0.5 µg/ml hydrocortisone, 20 ng/ml epidermal growth factor, 10 µg/ml insulin and 100 ng/ml cholera toxin. Cells were maintained at 37°C and 5% CO2 and were authenticated (LGC Standards, Teddington, UK) and confirmed to be mycoplasma free (Mycoalert, Lonza, Basel, Switzerland). shRNA (Thermo, Northumberland, UK). Virus particles released into the media were collected and purified via ultracentrifugation using Lenti-X concentrator (Clontech, Mountain View, USA). MCF7 cells were transduced with ATR shRNA lentivirus and stably expressing clones identified and grown by selection using 1 µg/ml puromycin. MCF7
shATR cells were maintained in full media supplemented with 1 µg/ml puromycin. shATR expression was induced by supplementing media with 1 µg/ml doxycycline. Cells grown in the absence of doxycycline were used as a control.
Gel electrophoresis and western blotting: Cells were prepared for gel electrophoresis by lysis using Phosphosafe extraction reagent (Merck, Darmstadt, Germany) and sonication.
Protein concentration was determined using a Pierce BCA protein assay (Thermo, Northumberland, UK). Lysates were diluted in 4 x XT sample buffer (Bio-Rad, Hemel
Hempstead, UK) and subjected to gel electrophoresis using 4-15% Tris-Glycine cells ( Buckinghamshire, UK) was detected using a G-box (Syngene, Cambridge, UK) and band intensities were measured by densitometry using Genetools software (Syngene, Cambridge, UK).
Growth assay: MCF7, MCF7 shATR or MDA-MB-231 cells were seeded at a density of 1000 cells/well into 96-well tissue culture plates. To assess the effect of ATR knockdown on cell growth MCF7 shATR cells were treated with 1 µg/ml doxycycline for 3 days prior to seeding then growth was measured over the next 11 days in fresh medium. For growth inhibition assays cells were treated for 24 hours with VE-821 then allowed to grow in fresh media for 5 days. Cells were fixed using Carnoy's fixative and allowed to dry overnight.
Cell growth was measured by staining cells with 10 µg/ml DAPI in 0.001% Triton-X-100.
Cells were solubilised using 10 mM EDTA (pH 2.2) and the fluorescence measured at 460 nm using a MFX Microtiter Plate Fluorimeter (Dynex Technologies, Chantilly, VA, USA).
Clonogenic survival assay: MCF7, MDA-MB-231 or MCF10A cells seeded at a density of 1 x 10 5 cells/ml. Following treatment with VE-821 for 24 hours cells were counted and reseeded at low density for colony formation. Colonies were allowed to grow for 2 weeks in fresh media before being fixed using Carnoy's fixative and stained using 1% crystal violet.
Colonies were counted and the % plating efficiency calculated.
RESULTS
ATR and pChk1 protein expression correlate to aggressive breast cancer phenotypes ATR: ATR was detected in the nuclei of the tumour cells with no cytoplasmic or membranneous expression. High ATR expression was seen in 409/1298 (31.5%) tumours compared to 889/1298 (68.5%) tumours that had low/negative ATR expression ( Figure 1A) ( Figure 1A ) ( Table   2 ). High cytoplasmic pChk1 protein expression was significantly associated with higher grade, higher mitotic index, nuclear pleomorphism, histological tumour type and lymphovascular invasion (p<0.05). Triple-negative and basal-like phenotypes were more likely in high cytoplasmic pChk1 protein expressing tumours (p<0.05). Absence/reduced expression of DDR proteins includingBRCA1, XRCC1, APE1, polβ, but increased expression of ATR and DNA-PKcs were also more likely associated with high cytoplasmic pChk1 protein expressing tumours (p<0.05). High MIB1, high TOPO2A, high CDK1 and low MDM2 was likely in high cytoplasmic pChk1 protein expressing tumours (p<0.05).
High nuclear pChk1 expression was seen in 264/1712 (15.4%) tumours compared to 1448/1712 (84.6%) tumours that had low nuclear pChk1 expression ( Figure 1A) (Supplementary Table S4 ). In contrast to cytoplasmic expression, low nuclear pChk1 protein expression was significantly associated with features of aggressive behaviour including higher grade, higher mitotic index, de-differentiation and nuclear pleomorphism (p<0.05).
ER-, PR-, AR-, Her-2 positive tumours were more likely in low nuclear pChk1protein expressing tumours (p<0.05). Absence of BRCA1, low XRCC1, low SMUG1, low APE1, low SMUG1, low polβ and low DNA-PKcs were also more likely associated with low nuclear pChk1 protein expressing tumours (p<0.05). High MIB1, low TOPO2A and low MDM2 was likely in low nuclear pChk1 protein expressing tumours (p<0.05).
ATR-pChk1 combined analysis:
The data presented above suggests that differential ATR/pChk1 expression may influence breast cancer phenotypes. To evaluate further, we performed ATR/pChk1 combined analysis. As shown in supplementary table S5, tumours that had high ATR expression/high cytoplasmic pChk1 expression/low nuclear pChk1 expression had larger size, higher stage, higher grade, higher mitotic index, dedifferentiation, pleomorphism, HER-2 overexpression, ER-/PR-/AR-, high MIB1, low TOP2A, low Bax and high CDK1 phenotypes (p<0.05). In addition, such tumours also exhibited a genomic instability phenotype characterised by absence of BRCA1, low XRCC1, low SMUG1, low polβ and low DNA-Pkcs expression (p<0.01). Interestingly, although there was no association with p53 mutation, low MDM2 was more likely in tumours with high ATR expression/high cytoplasmic pChk1 expression/low nuclear pChk1 expressing tumours.
ATR and pChk1 protein expression associate with poor survival outcomes in patients
Univariate analysis: High ATR expression was associated with worse breast cancer specific survival in patients (p=0.001) ( Figure 1B1 ). High cytoplasmic pChk1 expression was associated with shorter BCSS (p=0.005) ( Figure 1B2 ). In contrast, low nuclear pChk1 expression was associated with worse BCSS (p=0.007) (Supplementary Figure 1A) .
Investigating nuclear and cytoplasmic pChk1 together we found that patients whose tumours have low nuclear and high cytoplasmic Chk1 have the worst survival compared to tumours that have high nuclear and low cytoplasmic Chk1 (p<0.001) ( Figure 1B3 ). We then combined ATR and pChk1 in the analysis. As shown in figure 1B3 , high ATR/low nuclear Chk1/high cytoplasmic Chk1 tumours have the worst survival (p<0.001). As p53 may be involved in the activation of ATR-Chk1 pathway we also conducted an exploratory analysis in p53 mutant and proficient tumours. As shown in Figures 2A and 2B , high ATR/p53 mutants, high cytoplasmic pChk1/p53 mutants have the worst survival compared to tumours that are p53
wild-type. Similarly, high nuclear pChk1/p53 mutants have the worst survival compared to tumours that are p53 wild-type (Supplementary Figure 1B) .
We then proceeded to various sub-group analysis in ER+ and ER-breast cancer cohorts 
ATR and Chk1 mRNA expression in breast cancer
The data presented above provides evidence that high ATR and high Chk1 protein expression have prognostic significance in breast cancer. To investigate whether RNA of these genes are also associated with outcome and to assess the role of RNA-protein translation on the clinical signaificance of genes, , we explored ATR and Chk1 mRNA expression in the METABRIC cohort that comprises 1950 breast tumours (nature reference).
Interestingly, high ATR mRNA was not significantly associated with any clinicopathological features or survival in the METABRIC cohort ( Figure 2B , Supplementary Table S7, supplementary Figure 3A and supplementary Figure 3C ). On the other hand, as shown in supplementary table S8, high Chk1 mRNA was significantly associated with high tumour Tstage, high grade, lymph node positivity, high risk NPI score (>3.4), HER-2 over expression, ER negative, triple negative, and molecular classes associated with aggressive behaviour and poor outcome including Genefu subtypes (ER-/Her-2 negative, ER+/Her-2 negative/high proliferation), PAM50.Her-2, PAM50. Basal, integrative molecular cluster (intClust).1, intClust.5, intClust.9 and intClust.10 phenotypes (p<0.01). Patients with tumours that had high Chk1 mRNA had significantly shorter BCSS compared to tumours that had low Chk1 mRNA expression (p<00001) ( Figure 2C ). In ER+ tumours that received adjuvant endocrine therapy, high Chk1 mRNA was significantly associated with worse BCSS (p<0.001) (Supplementary Figure 3B) . Conversely, in ER-tumours that received adjuvant chemotherapy, high Chk1 mRNA was not associated with worse BCSS (Supplementary Figure 3D) .
Taken together, protein as well as mRNA expression data suggests that for ATR, protein over expression is likely to be due to a post-transcriptional/translational mechanism. However for Chk1, protein over expression is due to transcriptional up-regulation.
Replication stress induced phosphorylation of Chk1 at serine 345 is ATR dependent in breast cancer cells
Multivariate analysis in human tumours provides evidence that ATR independently influences survival in patients and is key biomarker. To provide further preclinical evidence we proceeded to mechanistic studies in breast cancer cell lines. We first generated ATR knockdown (KD) breast cancer cells using an ATR specific siRNA construct. As shown in Figure 3A1 and 3A2, we achieved more than 90% KD of ATR in MCF7 cells. 
ATR is required for breast cancer cell growth
To investigate whether ATR depletion has biological consequences in cells, we generated stable ATR KD MCF7 cells using doxycycline inducible shRNA. Following 3 days of treatment with doxycycline, robust KD of ATR was evident ( Figure 4A1 ). Doxycycline was then removed and cell were monitored for growth and ATR protein expression over 11 days.
As shown in Figure 4A1 and 4A2, ATR deficiency arrested cell growth. However upon reexpression of ATR, cell growth was restored. Doxycycline treatment alone in un-transfected MCF7 cells had no effect (supplementary Figure 4) .
We then investigated the effect of VE-821 in breast cancer cells. As shown in Figure 4B , a dose dependent suppression of cell growth was evident in MCF7 (GI50 = 0.25 μM) and in MDA-MB-231 cells (GI50 = 1.70 μM). There was also a significant direct correlation between growth inhibition and ATR inhibition in MCF7 and MDA-MB-231 cells ( Figure   4C ). To investigate whether VE-821 has selective toxicity to cancer cells, we performed clonogenic cell survival assays in MCF7, MDA-MB-231 and MCF10A cells. VE-821 exhibited selective toxicity in breast cancer cells (MCF7 and MDA-MB-23) compared to non-tumorigenic breast epithelium cells (MCF10A) ( Figure 4D ).
Taken together the preclinical study provides evidence that ATR is essential for breast cancer growth. In addition, the data also concurs with clinical study that demonstrated ATR overexpression as an independent prognostic factor in breast cancer.
DISCUSSION
ATR, a key factor in the maintenance of genomic integrity, is activated by single stranded (ss)-double stranded (ds) DNA junctions generated at stalled replication forks either during replication stress or during genotoxic therapy. Activated ATR in turn phosphorylates Chk1 at Ser 345 (pChk1) resulting in regulation of cell cycle progression and DNA repair. This is the first study to comprehensively investigate ATR and pChk1 in large cohorts of breast cancers.
The data presented here provides compelling evidence that ATR and pChk1 have prognostic and predictive significance in breast cancer.
Chk1 is a key mediator of checkpoint regulation, genomic stability and cellular survival. suggesting a genomic stability role for nuclear Chk1. Combined analysis also showed that tumours with high cytoplasmic/low nuclear pChk1 tumours have the worst survival compared with low cytoplasmic/high nuclear tumours implying that altered sub-cellular localisation of Chk1 has clinicopathological significance. A striking observation in the current study was that Chk1 mRNA overexpression was very highly significantly associated with aggressive phenotypes (such as lymph node positivity, high grade, high risk NPI score, ER+ luminal phenotype, Her-2 overexpression, triple negative phenotype) and poor survival. Chk1 mRNA levels were also linked to biologically distinct integrative clusters reported in the METABRIC study. High Chk1 mRNA level was frequent in intClust 10 subgroup which is the most highly genomically instable sub group with basal-like features. Whereas low Chk1 mRNA level was seen in intClust 3 subgroup that is characterised by low genomic instability.
In addition, high Chk1 mRNA level is also frequently seen in intClust 5 (HER-2 enriched with worst survival), intClust 9 (8q cis-acting/20qamplified mixed subgroup), and intClust 1 (17q23/20q cis-acting luminal B subgroup) subgroups that also manifest an aggressive phenotype. On the other hand, low Chk1 mRNA level is linked to intClust 4 (includes both ER-positive and ER-negative cases with a flat copy number landscape and termed the 'CNAdevoid' subgroup with extensive lymphocytic infiltration), intClust 7 (16p gain/16q loss with higher frequencies of 8q amplification luminal A subgroup) and intClust 8 subgroups (classical 1q gain/16q loss luminal A subgroup) (18). High Chk1 mRNA was associated with poor survival in the METABRIC cohort. Interestingly, intClust 10, intClust 9, intClust 5 and intClust 1 sub-groups that are associated with high Chk1 levels were also associated with poor prognosis in METABRIC study (18) .In contrast, intClust 3, intClust 4, intClust 7 and intClust 8 that are associated with low Chk1 expression, are associated with good to intermediate prognosis. In a study in triple negative breast cancer, Chk1was found to be overexpressed by transcriptional up-regulation through E2F1 Transcription factor. Similarly, in lung cancer and colorectal cancer high levels of Chk1 may be associated with poor differentiation and worse survival. Together the data provides further evidence that Chk1 is a key biomarker and a rational drug target in breast cancer.
A surprising observation in the METABRIC cohort was that ATR mRNA expression was not associated with any adverse clinicopathological features or survival implying that ATR protein overexpression is likely due to post-transcriptional/translational mechanisms. ATR protein overexpression was associated with aggressive tumours (such as high grade, size, higher mitotic index, pleomorphism) and poor survival. As proficient ATR and pChk1
indicate a functional ATR-Chk1 signalling pathway in cells, we performed combined analysis and demonstrated that tumours that are high ATR/high cytoplasmic pChk1/low nuclear Chk1 have the most aggressive phenotype and the worst survival.
Preclinical studies provide a link between p53 and ATR-Chk1 network. Loss of p53 may lead to increased replication stress and influence ATR/Chk1 expression. Interestingly, p53 deficient tumours appear to be sensitive to blockade by ATR or Chk1 inhibitors. In the current study, although there was no association with p53 mutation, low MDM2 was more likely in tumours with high ATR expression/ high cytoplasmic pChk1 expression /low nuclear pChk1 expressing tumours. We also demonstrate that ATR high/p53 mutants and Chk1 high/p53 mutants have the worst survival compared to that ATR low/p53 wild type and Chk1 high/p53 wild type. The data suggests that such breast cancer would be particularly suitable for personalized therapy.
An unexpected finding in the current study was a lack of clear evidence for predictive significance of ATR or Chk1 in breast cancer patients receiving adjuvant chemotherapy. At the mRNA level ATR or Chk1 , did not influence survival in ER-negative tumours receiving chemotherapy. At the protein level, only cytoplasmic pChk1 overexpression appears to be associated with worse survival in patients treated with CMF (cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy. Surprisingly, low cytoplasmic pChk1 was associated with poor survival in patients receiving anthracycline chemotherapy. This is in contrast to previous pre-clinical observation suggesting anthracycline sensitivity in Chk1 deficient cancer cell lines. Therefore further clinical studies are required to confirm these observations.
In the multivariate model, high ATR expression was independently associated with worse BCSS implying that ATR is an important prognostic biomarker in breast cancer. To provide additional evidence, we investigated in breast cancer cell lines. Firstly, we showed that ATR was directly involved in phosphorylation of Chk1 at serine 345 in breast cancer cells.
Secondly, ATR knock down reduced proliferation and survival. Thirdly, VE-821, a specific and potent small molecule inhibitor of ATR not only blocked ATR induced Chk1 phosphorylation but also reduced breast cancer cell survival in a dose dependent manner.
Taken together, the clinical and pre-clinical data provides compelling evidence that ATR is a promising target for anti-cancer therapy.
In conclusion, we provide confirmatory evidence that ATR-Chk1 influences breast cancer pathogenesis and clinical outcomes. Our data would support accelerated evaluation of ATR and Chk1 inhibitors currently under clinical development for personalized therapy in breast cancer patients. MCF7, MDA-MB-231 and MCF10A cells were seeded into 6-well tissue culture plates and allowed to adhere for 24 hours. Cells were treated with VE-821 for 24 hours before being counted and re-seeded for colony formation. Cells were then allowed to grow for 14 days.
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Colonies were then fixed, stained and counted.
